Raghvendra M Srivastava
Overview
Explore the profile of Raghvendra M Srivastava including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai Y, Nair K, Barot S, Xiang S, Kamath S, Melas M, et al.
J Natl Cancer Inst
. 2024 Jun;
116(10):1645-1653.
PMID: 38902947
The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early-onset CRC [EOCRC]) has substantially increased, and yet the etiology and molecular mechanisms underlying this alarming rise remain...
2.
Do M, Shi W, Ji L, Ladewig E, Zhang X, Srivastava R, et al.
Immunity
. 2023 Nov;
56(11):2555-2569.e5.
PMID: 37967531
Tumors develop by invoking a supportive environment characterized by aberrant angiogenesis and infiltration of tumor-associated macrophages (TAMs). In a transgenic model of breast cancer, we found that TAMs localized to...
3.
Vos J, Burman B, Jain S, Fitzgerald C, Sherman E, Dunn L, et al.
Nat Med
. 2023 Aug;
29(12):3077-3089.
PMID: 37620627
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) and ipilimumab (ipi, anti-CTLA-4) in 64 patients...
4.
Srivastava R, Thounaojam M, Marincola F, Shanker A
Front Immunol
. 2023 Jun;
14:1214843.
PMID: 37266417
No abstract available.
5.
Nixon B, Kuo F, Ji L, Liu M, Capistrano K, Do M, et al.
Immunity
. 2022 Oct;
55(11):2044-2058.e5.
PMID: 36288724
Tumors are populated by antigen-presenting cells (APCs) including macrophage subsets with distinct origins and functions. Here, we examined how cancer impacts mononuclear phagocytic APCs in a murine model of breast...
6.
Ma X, Riaz N, Samstein R, Lee M, Makarov V, Valero C, et al.
Nat Genet
. 2022 Jul;
54(7):996-1012.
PMID: 35817971
Defects in pathways governing genomic fidelity have been linked to improved response to immune checkpoint blockade therapy (ICB). Pathogenic POLE/POLD1 mutations can cause hypermutation, yet how diverse mutations in POLE/POLD1...
7.
Krishna C, DiNatale R, Kuo F, Srivastava R, Vuong L, Chowell D, et al.
Cancer Cell
. 2021 Apr;
39(5):662-677.e6.
PMID: 33861994
Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here we perform paired...
8.
Samstein R, Krishna C, Ma X, Pei X, Lee K, Makarov V, et al.
Nat Cancer
. 2021 Apr;
1(12):1188-1203.
PMID: 33834176
Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced cancer, but the determinants of response remain poorly understood. Here we report differential effects of mutations in the homologous...
9.
Srivastava R, Purohit T, Chan T
Semin Radiat Oncol
. 2020 May;
30(2):113-128.
PMID: 32381291
Cancer is the manifestation of uncontrolled cellular growth and immune escape mechanisms. Unrestrained tumor growth can be associated with incidental errors in the genome during replication and genotoxic agents can...
10.
Srivastava R, Marincola F, Shanker A
Front Immunol
. 2020 Jan;
10:2916.
PMID: 31921175
No abstract available.